Related Experiment Video
Updated: May 2, 2026

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model
Published on: March 9, 2022
[The treatment of mitochondrial disorders, present and future]
1Department of Pediatrics and Child Health, Kurume University School of Medicine.
Abstract:
Mitochondrial disorder has an inherited multi-system mitochondrial dysfunction that often involves the nervous, endocrine, renal and cardiac system. Although many molecular and cellular mechanisms leading to mitochondrial cytopathy have been discovered, clinical management of the disorders remains largely supportive. Many therapeutic drugs and reagents have been published effective in the past 20 years, however, none of those have been approved their efficacy by a double blind randomized placebo-controlled, or open labeled trial. In this review, we describe the current situation for developing the therapeutic drugs in mitochondrial disorders by clinical trial registry. We also describe the investigator-mediated clinical trial of L-arginine, and taurin for MELAS, and new project for developing the therapeutic drug of sodium pyruvate for lactic acidosis associated with mitochondrial disorders in Japan.
Insights
Developing effective treatments for inherited mitochondrial disorders remains challenging, with limited clinical trial approvals. This review examines current therapeutic drug development, including trials for L-arginine, taurine, and sodium pyruvate.
Area of Science:
- Biochemistry
- Genetics
- Clinical Medicine
Context:
- Mitochondrial disorders involve inherited multi-system dysfunction affecting major organs.
- Despite progress in understanding molecular mechanisms, clinical management is primarily supportive.
- No drug has demonstrated efficacy through rigorous double-blind, randomized, placebo-controlled trials.
Purpose:
- To review the current landscape of therapeutic drug development for mitochondrial disorders.
- To analyze data from clinical trial registries.
- To highlight specific investigator-mediated trials and new drug development projects in Japan.
Summary:
- This review examines the status of therapeutic drug development for mitochondrial disorders based on clinical trial data.
- It discusses ongoing trials for L-arginine and taurine in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes).
- A new project developing sodium pyruvate for mitochondrial disorder-associated lactic acidosis in Japan is also presented.
Impact:
- Provides an overview of the challenges and progress in clinical development for mitochondrial disorders.
- Identifies potential therapeutic avenues and ongoing research efforts.
- Informs researchers and clinicians about the current state of drug approval and development pipelines.
More Related Videos
08:39Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
Published on: September 16, 2020
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Animal Mitochondrial Genetics
Mitochondria
Mitochondrial Membranes
Mitochondrial Precursor Proteins
Most of the mitochondrial...
Mitochondrial Protein Sorting
Most of these mitochondrial proteins are encoded by the nucleus and imported to the mitochondria as unfolded or loosely folded precursors. Mitochondrial precursors...